IMPOYZ Drug Patent Profile
✉ Email this page to a colleague
When do Impoyz patents expire, and what generic alternatives are available?
Impoyz is a drug marketed by Primus Pharms and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-six patent family members in sixteen countries.
The generic ingredient in IMPOYZ is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Impoyz
A generic version of IMPOYZ was approved as clobetasol propionate by COSETTE on February 16th, 1994.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for IMPOYZ?
- What are the global sales for IMPOYZ?
- What is Average Wholesale Price for IMPOYZ?
Summary for IMPOYZ
| International Patents: | 26 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 81 |
| Patent Applications: | 4,476 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for IMPOYZ |
| What excipients (inactive ingredients) are in IMPOYZ? | IMPOYZ excipients list |
| DailyMed Link: | IMPOYZ at DailyMed |
Pharmacology for IMPOYZ
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Paragraph IV (Patent) Challenges for IMPOYZ
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| IMPOYZ | Cream | clobetasol propionate | 0.025% | 209483 | 1 | 2019-12-06 |
US Patents and Regulatory Information for IMPOYZ
IMPOYZ is protected by thirteen US patents.
Patents protecting IMPOYZ
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF MODERATE PLAQUE PSORIASIS
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PLAQUE PSORIASIS
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PSORIASIS
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
Topical compositions comprising a corticosteroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF MODERATE PLAQUE PSORIASIS
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PSORIASIS
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PLAQUE PSORIASIS
Topical formulations comprising a steroid
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: PLAQUE PSORIASIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primus Pharms | IMPOYZ | clobetasol propionate | CREAM;TOPICAL | 209483-001 | Nov 28, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Primus Pharms | IMPOYZ | clobetasol propionate | CREAM;TOPICAL | 209483-001 | Nov 28, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Primus Pharms | IMPOYZ | clobetasol propionate | CREAM;TOPICAL | 209483-001 | Nov 28, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Primus Pharms | IMPOYZ | clobetasol propionate | CREAM;TOPICAL | 209483-001 | Nov 28, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for IMPOYZ
See the table below for patents covering IMPOYZ around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2637447 | ⤷ Sign Up | |
| China | 107872972 | 包含皮质类固醇的外用组合物 (TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID) | ⤷ Sign Up |
| European Patent Office | 2473161 | COMPOSITIONS TOPIQUES CONTENANT UN STÉROÏDE (TOPICAL FORMULATIONS COMPRISING A STEROID) | ⤷ Sign Up |
| Canada | 2979051 | COMPOSITIONS TOPIQUES COMPRENANT UN CORTICOSTEROIDE (TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID) | ⤷ Sign Up |
| Australia | 2016228574 | Topical compositions comprising a corticosteroid | ⤷ Sign Up |
| Japan | 2021008505 | コルチコステロイドを含む局所用組成物 (TOPICAL COMPOSITIONS COMPRISING CORTICOSTEROID) | ⤷ Sign Up |
| Russian Federation | 2017134440 | Композиции для местного применения, содержащие кортикостероид | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
